Plus-size patients and TRT: Is 'poor care' a systemic problem?
Quick answer
The creator describes a pattern of weight-based dismissal across multiple primary care encounters spanning roughly 15 years, including denial of anxiety medication and failure to investigate symptoms beyond attributing them to weight. She also describes a negative informed consent experience involving a GLP-1 medication recommended without adequate explanation, likely around 2022 when semaglutide had recently received FDA approval for chronic weight management. No content in this video relates to testosterone replacement therapy, hypogonadism, or hormone optimization, despite the video being categorized under TRT.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @lifewithhanny actually say?
This is less a medical claim video and more a patient experience video. @lifewithhanny describes a string of negative encounters with doctors across about 15 years, most of them involving dismissal tied to her weight. The pattern she describes is specific: whenever she brought a health concern, providers defaulted to "it's just because you're overweight, you need to lose weight." She also describes being denied anxiety medication, being pressured toward GLP-1 drugs she'd never heard of, and being lectured about religion during a physical. The TRT category tag attached to this video doesn't match the content. She never mentions testosterone, hormones, or anything adjacent to TRT. That mismatch matters because it can send people looking for hormone-related information somewhere genuinely unhelpful.
Her core thesis is straightforward: patients deserve doctors who listen, and many don't get that, especially plus-size patients. That's not a fringe position. It's documented in peer-reviewed literature.
Does the science back this up?
Yes, more than most people want to admit. Weight bias in clinical settings is real, well-documented, and has measurable consequences for patient health outcomes. Studies consistently show that patients in larger bodies receive less diagnostic workup and more generic lifestyle advice than their thinner counterparts presenting with identical symptoms.
A 2016 survey published in Obesity Reviews (Alberga et al.) found that medical students and physicians hold strong implicit and explicit anti-fat biases, often comparable to racial bias in magnitude. A 2019 study in Patient Education and Counseling (Phelan et al.) found that patients who perceived weight stigma from their providers were significantly less likely to follow up on care, less likely to disclose symptoms, and more likely to delay future appointments. That last part is important: @lifewithhanny literally says she stopped going to the doctor for years after repeated bad experiences. The research predicts exactly that behavior.
On the anxiety medication piece, her account of being told to "just get over it" aligns with documented undertreatment of anxiety disorders in primary care, particularly in patients from stigmatized groups. That's not a conspiracy. It's a known gap in care delivery.
What did they get wrong (or right)?
She got the core dynamic right. Patients in larger bodies are frequently dismissed in clinical settings, and the consequences include delayed diagnoses, undertreated mental health conditions, and care avoidance. She's not exaggerating a fringe experience. She's describing something with a body of research behind it.
A few things are harder to evaluate. Her account of one provider "messing up" with a medication she was taking (she references "goby," likely Qelbree or possibly Gabi, though it's unclear) is unverifiable from a transcript. She doesn't give enough detail to assess whether that was a genuine clinical error or a misunderstanding, and it wouldn't be fair to draw conclusions either way.
The GLP-1 pressure she describes deserves a closer look. She frames a doctor recommending a GLP-1 medication as suspicious. At the time she describes (around 2022), semaglutide had already received FDA approval for chronic weight management in adults (Wegovy, June 2021). A provider recommending it wasn't doing something rogue. Whether that recommendation was appropriate for her specifically, without a full clinical picture, is unknowable. Her discomfort with an unfamiliar medication being pushed on her without explanation is a legitimate informed consent concern. The problem wasn't the drug. It was the communication.
What should you actually know?
If you've had experiences like hers, you're not alone and you're not being oversensitive. The medical literature is clear that weight bias affects the quality of care patients receive. A 2021 systematic review in Obesity Reviews (Tomiyama et al.) found that weight stigma is associated with increased mortality risk, partly through exactly the care-avoidance pathway @lifewithhanny describes.
Finding a primary care provider who takes your concerns seriously is not a luxury preference. It has real clinical implications. Patients with trusting provider relationships have better medication adherence, better preventive screening rates, and better chronic disease outcomes (Ha & Longnecker, 2010, Medical Principles and Practice).
On GLP-1 medications specifically: they're not something to fear because they're new, and they're not a cure-all to accept without a full conversation about risks, benefits, and alternatives. Any provider worth their license should be able to explain a medication recommendation in plain language before expecting you to agree to it.
One more thing: this video was tagged under TRT. She never mentions testosterone replacement therapy, hormones, or anything related. If you arrived here looking for TRT information, this video isn't a source for that.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Plus-size patients and TRT: Is 'poor care' a systemic problem?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Plus-size patients and TRT: Is 'poor care' a systemic problem? should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes a pattern of weight-based dismissal across multiple primary care encounters spanning roughly 15 years, including denial of anxiety medication and failure to investigate symptoms beyond attributing them to weight.
FormBlends verdict
The creator describes a pattern of weight-based dismissal across multiple primary care encounters spanning roughly 15 years, including denial of anxiety medication and failure to investigate symptoms beyond attributing them to weight. She also describes a negative informed consent experience involving a GLP-1 medication recommended without adequate explanation, likely around 2022 when semaglutide had recently received FDA approval for chronic weight management. No content in this video relates to testosterone replacement therapy, hypogonadism, or hormone optimization, despite the video being categorized under TRT.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes a pattern of weight-based dismissal across multiple primary care encounters spanning roughly 15 years, including denial of anxiety medication and failure to investigate symptoms beyond attributing them to weight. She also describes a negative informed consent experience involving a GLP-1 medication recommended without adequate explanation, likely around 2022 when semaglutide had recently received FDA approval for chronic weight management. No content in this video relates to testosterone replacement therapy, hypogonadism, or hormone optimization, despite the video being categorized under TRT.
- Weight bias in clinical settings is documented at scale: Alberga et al. (2016, Obesity Reviews) found anti-fat bias in medical trainees and physicians comparable in magnitude to racial bias on implicit association measures.
- Patients who perceive weight stigma from providers are significantly more likely to delay care and avoid follow-up appointments, a care-avoidance loop with direct health consequences (Phelan et al., 2019, Patient Education and Counseling).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Weight bias in clinical settings is documented at scale: Alberga et al. (2016, Obesity Reviews) found anti-fat bias in medical trainees and physicians comparable in magnitude to racial bias on implicit association measures.
- Patients who perceive weight stigma from providers are significantly more likely to delay care and avoid follow-up appointments, a care-avoidance loop with direct health consequences (Phelan et al., 2019, Patient Education and Counseling).
- Semaglutide (Wegovy) received FDA approval for chronic weight management in adults in June 2021. A provider recommending it around 2022 was not doing something off-label or experimental, though adequate patient explanation is required for informed consent.
- Tomiyama et al. (2021, Obesity Reviews) found in a systematic review that weight stigma is independently associated with increased mortality risk, operating partly through care avoidance pathways.
- This video contains no claims about testosterone, hormones, or TRT. Its categorization under TRT appears to be a metadata mismatch, not a reflection of the video's actual content.
- Trusting provider relationships improve measurable health outcomes including medication adherence and preventive screening rates, making provider selection a clinically relevant decision, not just a comfort preference (Ha & Longnecker, 2010, Medical Principles and Practice).
- Dismissing mental health symptoms as lifestyle issues rather than engaging with them clinically reflects a documented gap in primary care delivery, particularly for patients from stigmatized groups (Kessler et al., 2005, Archives of General Psychiatry).
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Hannah - Durham Blogger · TikTok creator
1.9K views on this video
its crazy to me now looking back that I thought it was normal to receive such poor care from my previous doctors. my current primary care physician at avance care is wonderful and I cannot say enough good things about her. she advocates for me, truly listens, and doesn't just say "well you need to lose weight" about everything. if you do not have a good relationship with your doctor, please advocate for yourself and shop around for a new one! both physical and mental health are important so find
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Hannah - Durham Blogger, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.